Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

Paul G. Richardson, Todd M. Zimmerman, Craig C. Hofmeister, Moshe Talpaz, Asher A Chanan Khan, Jonathan L. Kaufman, Jacob P. Laubach, Dharminder Chauhan, Andrzej J. Jakubowiak, Steven Reich, Mohit Trikha, Kenneth C. Anderson

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Marizomib (MRZ) is a novel, irreversible proteasome inhibitor in clinical development for the treatment of relapsed or relapsed and refractory multiple myeloma (RRMM). MRZ inhibits the 3 proteolytic activities of the 20S proteasome with specificity distinct from bortezomib and carfilzomib. Study NPI-0052-101 Part 1 enrolled relapsed or RRMM patients into an open-label, dose-escalation design to determine the maximum tolerated dose and recommended phase 2 dose (RP2D) of MRZ administered intravenously on 2 different schedules: schedule A (0.025-0.7 mg/m2 once weekly on days 1, 8, and 15 of 4-week cycles) and schedule B (0.15-0.6 mg/m2 twice weekly on days 1, 4, 8, and 11 of 3-week cycles; concomitant dexamethasone was allowed with schedule B). Patients had received an average of 4.9 and 7.3 prior treatment regimens (schedules A and B, respectively). MRZ schedule A was administered to 32 patients, and the RP2D was established as 0.7 mg/m2 infused over 10 minutes. Schedule B was administered to 36 patients, and the RP2D was determined to be 0.5 mg/m2 infused over 2 hours. The most common (>20% of patients) related adverse events were fatigue, headache, nausea, diarrhea, dizziness, and vomiting. Six patients achieved clinical benefit responses (defined as minimal response or better), including 5 partial responses (1 patient on schedule A and 4 on schedule B; 3 of these 4 patients received concomitant dexamethasone). MRZ was generally well tolerated, and results suggest activity in previously treated RRMM patients. Combination studies using pomalidomide and dexamethasone are now underway. The trial was registered at www.clinicaltrials.gov as #NCT00461045.

Original languageEnglish (US)
Pages (from-to)2693-2700
Number of pages8
JournalBlood
Volume127
Issue number22
DOIs
StatePublished - Jun 2 2016
Externally publishedYes

Fingerprint

Multiple Myeloma
Refractory materials
Appointments and Schedules
Dexamethasone
Proteasome Inhibitors
Proteasome Endopeptidase Complex
marizomib
Labels
Maximum Tolerated Dose
Dizziness
Fatigue of materials
Nausea
Vomiting
Fatigue
Headache
Diarrhea
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Richardson, P. G., Zimmerman, T. M., Hofmeister, C. C., Talpaz, M., Chanan Khan, A. A., Kaufman, J. L., ... Anderson, K. C. (2016). Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood, 127(22), 2693-2700. https://doi.org/10.1182/blood-2015-12-686378

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma : NPI-0052-101 Part 1. / Richardson, Paul G.; Zimmerman, Todd M.; Hofmeister, Craig C.; Talpaz, Moshe; Chanan Khan, Asher A; Kaufman, Jonathan L.; Laubach, Jacob P.; Chauhan, Dharminder; Jakubowiak, Andrzej J.; Reich, Steven; Trikha, Mohit; Anderson, Kenneth C.

In: Blood, Vol. 127, No. 22, 02.06.2016, p. 2693-2700.

Research output: Contribution to journalArticle

Richardson, PG, Zimmerman, TM, Hofmeister, CC, Talpaz, M, Chanan Khan, AA, Kaufman, JL, Laubach, JP, Chauhan, D, Jakubowiak, AJ, Reich, S, Trikha, M & Anderson, KC 2016, 'Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1', Blood, vol. 127, no. 22, pp. 2693-2700. https://doi.org/10.1182/blood-2015-12-686378
Richardson, Paul G. ; Zimmerman, Todd M. ; Hofmeister, Craig C. ; Talpaz, Moshe ; Chanan Khan, Asher A ; Kaufman, Jonathan L. ; Laubach, Jacob P. ; Chauhan, Dharminder ; Jakubowiak, Andrzej J. ; Reich, Steven ; Trikha, Mohit ; Anderson, Kenneth C. / Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma : NPI-0052-101 Part 1. In: Blood. 2016 ; Vol. 127, No. 22. pp. 2693-2700.
@article{bb049040c0884eb4a2fe28ce538baf37,
title = "Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1",
abstract = "Marizomib (MRZ) is a novel, irreversible proteasome inhibitor in clinical development for the treatment of relapsed or relapsed and refractory multiple myeloma (RRMM). MRZ inhibits the 3 proteolytic activities of the 20S proteasome with specificity distinct from bortezomib and carfilzomib. Study NPI-0052-101 Part 1 enrolled relapsed or RRMM patients into an open-label, dose-escalation design to determine the maximum tolerated dose and recommended phase 2 dose (RP2D) of MRZ administered intravenously on 2 different schedules: schedule A (0.025-0.7 mg/m2 once weekly on days 1, 8, and 15 of 4-week cycles) and schedule B (0.15-0.6 mg/m2 twice weekly on days 1, 4, 8, and 11 of 3-week cycles; concomitant dexamethasone was allowed with schedule B). Patients had received an average of 4.9 and 7.3 prior treatment regimens (schedules A and B, respectively). MRZ schedule A was administered to 32 patients, and the RP2D was established as 0.7 mg/m2 infused over 10 minutes. Schedule B was administered to 36 patients, and the RP2D was determined to be 0.5 mg/m2 infused over 2 hours. The most common (>20{\%} of patients) related adverse events were fatigue, headache, nausea, diarrhea, dizziness, and vomiting. Six patients achieved clinical benefit responses (defined as minimal response or better), including 5 partial responses (1 patient on schedule A and 4 on schedule B; 3 of these 4 patients received concomitant dexamethasone). MRZ was generally well tolerated, and results suggest activity in previously treated RRMM patients. Combination studies using pomalidomide and dexamethasone are now underway. The trial was registered at www.clinicaltrials.gov as #NCT00461045.",
author = "Richardson, {Paul G.} and Zimmerman, {Todd M.} and Hofmeister, {Craig C.} and Moshe Talpaz and {Chanan Khan}, {Asher A} and Kaufman, {Jonathan L.} and Laubach, {Jacob P.} and Dharminder Chauhan and Jakubowiak, {Andrzej J.} and Steven Reich and Mohit Trikha and Anderson, {Kenneth C.}",
year = "2016",
month = "6",
day = "2",
doi = "10.1182/blood-2015-12-686378",
language = "English (US)",
volume = "127",
pages = "2693--2700",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "22",

}

TY - JOUR

T1 - Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma

T2 - NPI-0052-101 Part 1

AU - Richardson, Paul G.

AU - Zimmerman, Todd M.

AU - Hofmeister, Craig C.

AU - Talpaz, Moshe

AU - Chanan Khan, Asher A

AU - Kaufman, Jonathan L.

AU - Laubach, Jacob P.

AU - Chauhan, Dharminder

AU - Jakubowiak, Andrzej J.

AU - Reich, Steven

AU - Trikha, Mohit

AU - Anderson, Kenneth C.

PY - 2016/6/2

Y1 - 2016/6/2

N2 - Marizomib (MRZ) is a novel, irreversible proteasome inhibitor in clinical development for the treatment of relapsed or relapsed and refractory multiple myeloma (RRMM). MRZ inhibits the 3 proteolytic activities of the 20S proteasome with specificity distinct from bortezomib and carfilzomib. Study NPI-0052-101 Part 1 enrolled relapsed or RRMM patients into an open-label, dose-escalation design to determine the maximum tolerated dose and recommended phase 2 dose (RP2D) of MRZ administered intravenously on 2 different schedules: schedule A (0.025-0.7 mg/m2 once weekly on days 1, 8, and 15 of 4-week cycles) and schedule B (0.15-0.6 mg/m2 twice weekly on days 1, 4, 8, and 11 of 3-week cycles; concomitant dexamethasone was allowed with schedule B). Patients had received an average of 4.9 and 7.3 prior treatment regimens (schedules A and B, respectively). MRZ schedule A was administered to 32 patients, and the RP2D was established as 0.7 mg/m2 infused over 10 minutes. Schedule B was administered to 36 patients, and the RP2D was determined to be 0.5 mg/m2 infused over 2 hours. The most common (>20% of patients) related adverse events were fatigue, headache, nausea, diarrhea, dizziness, and vomiting. Six patients achieved clinical benefit responses (defined as minimal response or better), including 5 partial responses (1 patient on schedule A and 4 on schedule B; 3 of these 4 patients received concomitant dexamethasone). MRZ was generally well tolerated, and results suggest activity in previously treated RRMM patients. Combination studies using pomalidomide and dexamethasone are now underway. The trial was registered at www.clinicaltrials.gov as #NCT00461045.

AB - Marizomib (MRZ) is a novel, irreversible proteasome inhibitor in clinical development for the treatment of relapsed or relapsed and refractory multiple myeloma (RRMM). MRZ inhibits the 3 proteolytic activities of the 20S proteasome with specificity distinct from bortezomib and carfilzomib. Study NPI-0052-101 Part 1 enrolled relapsed or RRMM patients into an open-label, dose-escalation design to determine the maximum tolerated dose and recommended phase 2 dose (RP2D) of MRZ administered intravenously on 2 different schedules: schedule A (0.025-0.7 mg/m2 once weekly on days 1, 8, and 15 of 4-week cycles) and schedule B (0.15-0.6 mg/m2 twice weekly on days 1, 4, 8, and 11 of 3-week cycles; concomitant dexamethasone was allowed with schedule B). Patients had received an average of 4.9 and 7.3 prior treatment regimens (schedules A and B, respectively). MRZ schedule A was administered to 32 patients, and the RP2D was established as 0.7 mg/m2 infused over 10 minutes. Schedule B was administered to 36 patients, and the RP2D was determined to be 0.5 mg/m2 infused over 2 hours. The most common (>20% of patients) related adverse events were fatigue, headache, nausea, diarrhea, dizziness, and vomiting. Six patients achieved clinical benefit responses (defined as minimal response or better), including 5 partial responses (1 patient on schedule A and 4 on schedule B; 3 of these 4 patients received concomitant dexamethasone). MRZ was generally well tolerated, and results suggest activity in previously treated RRMM patients. Combination studies using pomalidomide and dexamethasone are now underway. The trial was registered at www.clinicaltrials.gov as #NCT00461045.

UR - http://www.scopus.com/inward/record.url?scp=84974575364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974575364&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-12-686378

DO - 10.1182/blood-2015-12-686378

M3 - Article

C2 - 27009059

AN - SCOPUS:84974575364

VL - 127

SP - 2693

EP - 2700

JO - Blood

JF - Blood

SN - 0006-4971

IS - 22

ER -